John Oyler, BeiGene CEO (Endpoints News, PharmCube)

BeiGene ends pact with Shore­line, its 'en­try in­to cell ther­a­py'

BeiGene said its four-tar­get nat­ur­al killer cell ther­a­py col­lab­o­ra­tion with Shore­line Bio­sciences is over. And by reneg­ing on Shore­line’s iP­SC-NK cell tech­nol­o­gy, BeiGene los­es its “en­try in­to cell ther­a­py,” a phrase used to de­scribe the tie-up in an in­vestor pre­sen­ta­tion last year.

BeiGene, which re­port­ed that rev­enue in 2023 was 74% high­er than in 2022, said Mon­day the pact was ter­mi­nat­ed ear­li­er this year. The biotech had ini­tial­ly doled out $45 mil­lion up­front in Jan­u­ary 2022, af­ter the part­ners dis­closed the agree­ment in June 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.